| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA130090
Max Phase: Preclinical
Molecular Formula: C15H13N3O4S
Molecular Weight: 331.35
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: COC(=O)Nc1nc2cc(C(=O)c3cc(CO)cs3)ccc2[nH]1
Standard InChI: InChI=1S/C15H13N3O4S/c1-22-15(21)18-14-16-10-3-2-9(5-11(10)17-14)13(20)12-4-8(6-19)7-23-12/h2-5,7,19H,6H2,1H3,(H2,16,17,18,21)
Standard InChI Key: PRMSXBKAEWYKDJ-UHFFFAOYSA-N
Associated Targets(non-human)
Tubulin alpha chain 497 Activities
B16 5829 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 331.35 | Molecular Weight (Monoisotopic): 331.0627 | AlogP: 2.53 | #Rotatable Bonds: 4 |
| Polar Surface Area: 104.31 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 9.11 | CX Basic pKa: 3.34 | CX LogP: 2.41 | CX LogD: 2.40 |
| Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.64 | Np Likeness Score: -0.97 |
References
| 1. Kruse LI, Ladd DL, Harrsch PB, McCabe FL, Mong SM, Faucette L, Johnson R.. (1989) Synthesis, tubulin binding, antineoplastic evaluation, and structure-activity relationship of oncodazole analogues., 32 (2): [PMID:2913301] [10.1021/jm00122a020] |
Source
Source(1):